BACKGROUND: The European Union Summary of Product Characteristics (EU SmPC) for alemtuzumab in multiple sclerosis (MS) was revised in January 2020 under an Article 20 EU-pharmacovigilance procedure to include a revised indication, additional contraindications, and new monitoring requirements. OBJECTIVES: To evaluate adherence to the revised SmPC for alemtuzumab across four European countries.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Jian-Yu
Contact Jian-Yu, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack